The following new grants were awarded to JCCC members, announced in March 2012:
Sponsor Name: Threshold Pharmaceuticals
Award Title: Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Principal Investigator: Garon, Edward
Sponsor Name: Inc Research
Award Title: Randomized Double Blind Phase 3 Efficacy and Safety Study OF PF-00299804 Versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer Following Progression after, or Intolerance to, at Least One Prior Chemotherapy
Principal Investigator: Hecht, J.
Sponsor Name: Hoffmann-La Roche Inc.(Include Roche Molecular Systems, Inc.
Award Title: Randomized, Multicenter, Open-label Phase II Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With KRAS Wild-type or Mutant Metastatic Colorectal Cancer
Principal Investigator: Herschman, Harvey
Sponsor Name: American Society of Hematology
Award Title: Zaiss, Anne: The Role of Heparan Sulfate and Hepatic Lipoprotein Receptors on Factor X-Dependent Adenovirus Transduction In Vivo
Principal Investigator: Kabbinavar, Fairooz
Sponsor Name: Roche Diagnostics
Award Title: Roche Diagnostics Anti-Angiogenesis: Five Programs
Principal Investigator: Kwon, Ohyun
Sponsor Name: Agensys, Inc.
Award Title: Agensys/Kwon: Epothilone-Derivative Synthesis Collaboration
Principal Investigator: Liau, Linda
Sponsor Name: NIH/National Institute of Neurological Disorders & Stroke
Award Title: UCLA Neurosurgery Research Training and Education Program